Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 곽혜선 | * |
dc.contributor.author | 송곤진 | * |
dc.date.accessioned | 2021-08-05T16:31:02Z | - |
dc.date.available | 2021-08-05T16:31:02Z | - |
dc.date.issued | 2021 | * |
dc.identifier.issn | 2075-4426 | * |
dc.identifier.other | OAK-29706 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/258445 | - |
dc.description.abstract | Purpose: Cytochrome P450 (CYP) is involved in the metabolism of statins; CYP3A5 is the main enzyme responsible for lipophilic statin metabolism. However, the evidence of the association between CYP3A5*3 polymorphism and the risk of statin-induced adverse events remains unclear. Therefore, this study aimed to perform a systematic review and meta-analysis to investigate the relationship between the CYP3A5*3 polymorphism and the risk of statin-induced adverse events. Methods: The PubMed, Web of Science, and EMBASE databases were searched for qualified studies published until August 2020. Observational studies that included the association between statin-induced adverse events and the CYP3A5*3 polymorphism were reviewed. The odds ratios (ORs) and 95% confidence intervals (CIs) were evaluated to assess the strength of the relationship. The Mantel-Haenszel method was used to provide the pooled ORs. Heterogeneity was estimated with I-2 statistics and publication bias was determined by Begg's and Egger's test of the funnel plot. Data analysis was performed using Review Manager (version 5.4) and R Studio (version 3.6). Results: In total, data from 8 studies involving 1614 patients were included in this meta-analysis. The CYP3A5*3 polymorphism was found to be associated with the risk of statin-induced adverse events (*3/*3 vs. *1/*1 + *1/*3: OR = 1.40, 95% CI = 1.08-1.82). For myopathy, the pooled OR was 1.30 (95% CI: 0.96-1.75). The subgroup analysis of statin-induced myopathy revealed a trend, which did not achieve statistical significance. Conclusions: This meta-analysis demonstrated that the CYP3A5*3 polymorphism affected statin-induced adverse event risk. Therefore, CYP3A5 genotyping may be useful to predict statin toxicity. | * |
dc.language | English | * |
dc.publisher | MDPI | * |
dc.subject | statin | * |
dc.subject | adverse event | * |
dc.subject | pharmacogenomics | * |
dc.subject | systematic review | * |
dc.subject | meta-analysis | * |
dc.title | Association between CYP3A5 Polymorphism and Statin-Induced Adverse Events: A Systemic Review and Meta-Analysis | * |
dc.type | Review | * |
dc.relation.issue | 7 | * |
dc.relation.volume | 11 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.journaltitle | JOURNAL OF PERSONALIZED MEDICINE | * |
dc.identifier.doi | 10.3390/jpm11070677 | * |
dc.identifier.wosid | WOS:000676552400001 | * |
dc.identifier.scopusid | 2-s2.0-85111384336 | * |
dc.author.google | Yee, Jeong | * |
dc.author.google | Kim, Hamin | * |
dc.author.google | Heo, Yunhee | * |
dc.author.google | Yoon, Ha-Young | * |
dc.author.google | Song, Gonjin | * |
dc.author.google | Gwak, Hye-Sun | * |
dc.contributor.scopusid | 송곤진(57208326415) | * |
dc.date.modifydate | 20240422115307 | * |